SKU LUM-PT141-10 · C₅₀H₆₈N₁₄O₁₀ · 1025.18 g/mol · CAS 189691-06-3
A cyclic heptapeptide melanocortin-receptor agonist (MC4R-selective). Investigated for central nervous system signaling and behavioral pharmacology.
Purity (HPLC)
≥ 99.2%
Net peptide
5.00 mg ± 2%
Endotoxin
< 0.5 EU/mg
Format
Lyophilized vial
Storage
−20 °C, desiccated
Shelf life
24 months from MFG
$50CAD/ 10 mg vial
In stock · Lot LM-2660
Qty
Add $300 for Free shipping
HPLC + MS verified per lot
~4 days to your door
COA bundled with shipment
Lot samples retained 5 years
Overview
PT-141 (bremelanotide) is a synthetic cyclic seven-residue analog of α-MSH with high affinity for the melanocortin-4 receptor (MC4R) and lower affinity for MC1R/MC3R/MC5R. It is investigated as a tool compound for central melanocortin-system pharmacology.
Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped ~4 days from our lab.
Research applications
MC4R agonism potency assays, comparative MC1-5R selectivity screens, behavioral pharmacology in rodent models, and structural studies of the melanocortin-pharmacophore.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
Identity
Parameter
Value
Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular formula
C₅₀H₆₈N₁₄O₁₀
Molecular weight
1025.18 g/mol
CAS number
189691-06-3
Length
7 residues (cyclic)
Quality
Test
Specification
HPLC purity
99.11%
Mass confirmation
ESI-MS within 0.5 Da
Net peptide content
≥ 80% by AAA
Endotoxin
< 0.5 EU/mg (LAL)
Bioburden
< 10 CFU/g
Residual TFA
< 1.0%
Lot LM-2660
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Canada. Retain samples held under storage spec for five years from release date.
Verification
Method
Result
RP-HPLC at 220 nm
99.11% main peak
ESI-MS (positive)
1025.2 Da (theor. 1025.18)
Amino acid analysis
82.1% net peptide
LAL endotoxin
< 0.05 EU/mg
Karl Fischer (water)
2.8% w/w
Reconstitution
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Storage after reconstitution
Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Selected references
Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):899–908.
Pt 141 is a melanocortin receptor agonist, classified within the central nervous system signaling pathway. Structurally it is a synthetic α-MSH analog. Bremelanotide (PT-141) is a synthetic cyclic 7-residue melanocortin agonist with affinity for the MC3R and MC4R subtypes. Diamond et al. (2006) characterized its central effects in animal and clinical pharmacology.
In an in-vitro setting, Pt 141 interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable until reconstituted.
Common research applications
In-vitro receptor-binding and dose-response screens against the central nervous system signaling target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Pt 141's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.
Storage & handling
Pt 141 arrives lyophilized in Canada Post (~4 days). On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
References
Diamond LE et al. J Sex Med. 2006;3(4):628-38.
Pfaus JG et al. Pharmacol Biochem Behav. 2007;87(1):65-72.
Kingsberg SA et al. Obstet Gynecol. 2019;134(5):899-908.
For laboratory research only. Pt 141 is sold strictly as an in-vitro reference standard. Sold as an in-vitro reference standard, not as a Health Canada or FDA-approved therapeutic.
